In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uroboros Technologies LLC

www.uroborostech.com

Latest From Uroboros Technologies LLC

Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups

Second-generation therapeutics are moving into the clinic following Celgene’s successful gamble on Abraxane. New nanobiotechs proliferate, but an industry burned by other promising technology revolutions remains somewhat wary of investing in early-stage firms.

BioPharmaceutical Europe

Start-Up Previews, March 2013

This Month's Profile Group: Nanomedicine: Will It Get Big?, features profiles of Blend Therapeutics, Kala Pharmaceuticals, Qualiber, and Uroboros Technologies. Plus these Start-Ups Across Health Care: Ceterix Orthopaedics, Flux Medical, Neuros Medical, and Tunitas Therapeutics.

BioPharmaceutical Medical Device

Uroboros Technologies LLC

Biotechnology companies almost always talk about the precise molecular targets their drugs are intended to hit. But targets per se aren’t seen as particularly important at Uroboros Technologies LLC, which aims to turn DNA nanoparticles into cancer therapeutics. Rather than pursue defined targets, the San Diego-based start-up just wants to find particles that bind to cancer cells and not to normal ones.

BioPharmaceutical Nanotechnology

Nanomedicine: Will It Get Big?

Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Uroboros Technologies LLC
  • Senior Management
  • Bradley Messmer, PhD, Acting CEO
  • Contact Info
  • Uroboros Technologies LLC
    Phone: (858) 248-9253
    5448 Pire Ave.
    San Diego, CA 92122
    USA
UsernamePublicRestriction

Register